Skip to search boxSkip to navigationSkip to main content

Therapeutic options for patients with clonal and idiopathic hypereosinophia

  • Alfonso Quintás-Cardama(corresponding author)
    ,
*Corresponding author for this work
  • University of Texas MD Anderson Cancer Center
Scholary Output:
Contribution to journal
Review article
Research
Peer-review

Abstract

<p>Background: The hypereosinophilic syndrome (HES) comprises a heterogeneous group of disorders characterized by chronic, unexplained hypereosinophilia with organ involvement. The discovery of novel molecular targets has changed the therapeutic paradigm in HES. Objective: This article reviews the current medical management of patients with clonal and idiopathic hypereosinophilia with a particular emphasis on emerging new targeted therapies. Methods: The information contain in this review was obtained from public sources such as Journals and scientific meeting abstracts. The opinions expressed in this review are solely those of the authors. Results/Conclusion: The development of Imatinib-resistant mutations in the FIP1L1-PDGFR-α kinase domain has spurred the development of an array of new tyrosine kinas inhibitors. Moreover, the elucidation of the role of interleukin-5 in the pathogenesis of the lymphocytic variant of HES and the fact that CD52 is expressed on the surface of eosinophils and T cells have led to the clinical use of monoclonal antibodies such as mepolizumab, reslizumumab, and alemtuzymab for the treatment of different forms of hypereosinophilia.</p>

Publication Information

Output type

Scholary Output:
Contribution to journal
Review article
Research
Peer-review

Original language

English (US)

Pages from-to (Number of pages)

Pages 1039-1050 (12 pages)

Journal (Volume, Issue Number)

Expert Opinion on Investigational Drugs (Volume 17, Issue 7)

Publication milestones

  • Published - 07/2008

Publication status

Published - 07/2008

ISSN

1354-3784

Publication IDs

  • Scopus: 48249155731
  • PubMed: 18549340

Publication metrics

Metrics

Scopus
citations
SciVal
citations
4
Fractional count
1
Fractional count
0.50
Fractional count
1
Fractional count
0.50
Fractional count
1
Fractional count
1
SciVal
FWCI
0.31
SciVal
Author count
2
SciVal
Paper percentile
47

PlumX, opens in new tab

Citation count
7
Captures
11

Funding Details

J Cortes has received grant support from Novartis, BMS, and Wyeth.
FundersFunding number
NCI
P30CA016672
BMS
-
Novartis
-